Intellia Therapeutics
Trade Intellia Therapeutics 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About NTLA
Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases.
NTLA Key Statistics
Stock Snapshot
The current Intellia Therapeutics(NTLA) stock price is $10.42, with a market capitalization of 1.2B. The stock trades at a price-to-earnings (P/E) ratio of -2.43.
As of 2026-01-11, Intellia Therapeutics(NTLA) stock has fluctuated between $10.13 and $10.98. The current price stands at $10.42, placing the stock +2.9% above today's low and -5.1% off the high.
The Intellia Therapeutics(NTLA)'s current trading volume is 6.87M, compared to an average daily volume of 4.26M.
In the last year, Intellia Therapeutics(NTLA) shares hit a 52-week high of $28.25 and a 52-week low of $5.90.
In the last year, Intellia Therapeutics(NTLA) shares hit a 52-week high of $28.25 and a 52-week low of $5.90.
NTLA News
Insiders have been trading these 5 stocks: ((SNPS)), ((RDDT)), ((NTLA)), ((SYM)) and ((STX)). Here is a breakdown of their recent trades and their value. Claim...
Claim 70% Off TipRanks Premium Intellia Therapeutics ( (NTLA) ) just unveiled an update. On January 9, 2026, Intellia Therapeutics updated its corporate prese...
As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money. So let's look at tw...
Analyst ratings
52%
of 27 ratingsMore NTLA News
New insider activity at Intellia Therapeutics ( (NTLA) ) has taken place on January 7, 2026. Claim 70% Off TipRanks Premium Unlock hedge fund-level data and pow...
In late 2025, Intellia Therapeutics paused dosing and enrollment in its late-stage MAGNITUDE trials for nexiguran ziclumeran after a patient death from severe l...
BofA lowered the firm’s price target on Intellia Therapeutics (NTLA) to $12 from $14 and keeps a Neutral rating on the shares. The firm is updating its price ta...